Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Peptide Vaccine

Phase 2Vaccine

UUniversity Hospital Tuebingen

Peptide Vaccine is one of 133 biologic programs targeting Melanoma. It is currently in Phase 2.

5

Indications

12

Total Trials

2

Active Trials

132

Competitors

Pipeline

Status by Indication[3][1]

Indication

MelanomaActive, not recruiting

Renal Cell CarcinomaActive, not recruiting

Gastric CancerActive, not recruiting

GlioblastomaActive, not recruiting

KidneyRecruiting

MelanomaPhase 1

Active, not recruiting

Renal Cell CarcinomaPhase 1/Phase 2

Active, not recruiting

Gastric CancerPhase 1

Active, not recruiting

GlioblastomaPhase 2

Active, not recruiting

KidneyPhase 1

Recruiting

Competition

Competitive Landscape

947 competitors in Melanoma

#DrugCompanyPhaseTrials

Tuoyi

SSun Yat-sen University

ABI-007

Bristol-Myers Squibb

Intismeran Autogene

Masitinib

GSK2118436

Lymphoseek

NNavidea Biopharmaceuticals

Vusolimogene Oderparepvec

Peptide Vaccine

UUniversity Hospital Tuebingen

Zelboraf

CConrado Roberto Hoffmann Filho

Isolated Limb Perfusion

MMemorial Sloan Kettering Cancer Center

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2027

Phase 1Recruiting

Kidney

NCT06741072

Q3 2029

Phase 1/2Recruiting

Resistance

NCT05950139

Clinical

Trials by Indication[1]

Glioblastoma1 trial

A Toll-like Receptor Agonist as an Adjuvant to Tumor Associated Antigens (TAA) Mixed With Montanide ISA-51 VG With Bevacizumab for Patients With Recurrent Glioblastoma

Withdrawn·NNYU Langone Health·Phase 2·NCT02754362

Biochemical Recurrence1 trial

Peptide-specific Vaccination in HLA-A*02 Positive Patients With Biochemical Recurrence After Radical Prostatectomy

Unknown status·UUniversity Hospital Tuebingen·Phase 1/2·NCT02452307·36 enrolled

Melanoma1 trial

Vaccine Therapy in Treating Patients With Recurrent Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery

Completed·AAhmad Tarhini·Phase 1·NCT00471471·22 enrolled

First Line Therapy1 trial

iVAC-CLL01: Patient-individualized Peptide Vaccination After First Line Therapy of CLL

Completed·UUniversity Hospital Tuebingen·Phase 2·NCT02802943·56 enrolled

Gastric Cancer1 trial

Human Leukocyte Antigen (HLA) - A*2402 Restricted Peptide Vaccine Therapy in Patients With Advanced Gastric Cancer

Completed·KKinki University·Phase 1·NCT00845611·9 enrolled

7 more indications

Treatment1 trial

PSMA and TARP Peptide Vaccine With Poly IC-LC Adjuvant in HLA-A2 (+) Patients With Elevated PSA After Initial Definitive Treatment

Completed·HH. Lee Moffitt Cancer Center and Research Institute·N/A·NCT00694551·29 enrolled

Resistance1 trial

Peptide Vaccine To Prevent Acquired Resistance In Patients With Advanced ALK+ NSCLC

Recruiting·SSidney Kimmel Comprehensive Cancer Center at Johns Hopkins·Phase 1/2·NCT05950139·12 enrolled

Renal Cell Carcinoma1 trial

Adjuvant Antigen Specific Immunotherapy in Patients With Advanced Renal Cell Carcinoma Using Tumor Associated Peptides

Unknown status·UUniversity Hospital Tuebingen·Phase 1/2·NCT02429440·40 enrolled

Adjuvant1 trial

Proteinase 3 PR1 Peptide Mixed With Montanide ISA-51 VG Adjuvant and Administered With GM-CSF and PEG-INTRON(R)

Terminated·MM.D. Anderson Cancer Center·Phase 2·NCT00415857·5 enrolled

Immunization1 trial

Immunization With HIV-1 Peptides in Adjuvant for Treatment of Patients With Chronic HIV-infection

Completed·GGitte Kronborg·Phase 1·NCT01009762·11 enrolled

Malignancies1 trial

A Novel Vaccine for the Treatment of MUC1-expressing Tumor Malignancies

Withdrawn·HHadassah Medical Organization·Phase 2·NCT00162500·15 enrolled

Kidney1 trial

A Phase 1B Double Blinded Randomized Trial Evaluating Safety, Tolerability, and Immune Response of OSU-2131 a BZLF1 Peptide Vaccine With Stimulon™ QS-21 Solution Adjuvant in Healthy Volunteers and Patients Awaiting Solid Organ Transplantation

Recruiting·OOhio State University Comprehensive Cancer Center·Phase 1·NCT06741072·55 enrolled

Sources

References

[1]
ClinicalTrials.gov — 12 trial records for Peptide Vaccine. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Peptide Vaccine compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Peptide Vaccine. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — University Hospital Tuebingen company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Vaccine[2]
Highest Phase: Phase 2[1]
Company: UUniversity Hospital Tuebingen

Related News